ID   VACO 481
AC   CVCL_8638
SY   Vaco 481; VACO481; Vaco481; V481
DR   EFO; EFO_0022534
DR   cancercelllines; CVCL_8638
DR   ColonAtlas; VACO481
DR   Cosmic; 1090615
DR   Cosmic; 1131690
DR   Cosmic; 2646665
DR   Cosmic; 2650773
DR   Cosmic; 2667970
DR   Cosmic; 2727477
DR   GEO; GSM1448110
DR   Wikidata; Q54992758
RX   PubMed=7704014;
RX   PubMed=7761852;
RX   PubMed=8385345;
RX   PubMed=8755562;
RX   PubMed=9515795;
RX   PubMed=9715273;
RX   PubMed=11314036;
RX   PubMed=12615714;
RX   PubMed=17363507;
RX   PubMed=25926053;
CC   Microsatellite instability: Instable (MSI) (PubMed=25926053).
CC   Sequence variation: Mutation; HGNC; HGNC:173; ACVR2A; Simple; p.Asp96fs*4 (c.278_279insA); Zygosity=Heterozygous (PubMed=12615714).
CC   Sequence variation: Mutation; HGNC; HGNC:173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (PubMed=12615714).
CC   Sequence variation: Mutation; HGNC; HGNC:11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (PubMed=12615714).
CC   Sequence variation: Mutation; HGNC; HGNC:11773; TGFBR2; Simple; p.Ala535fs*30 (c.1597_1598TG[4]) (c.1602_1603insTG); ClinVar=VCV000012501; Zygosity=Heterozygous (PubMed=12615714).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=9715273).
CC   Omics: Transcriptome analysis by microarray.
ST   Source(s): PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 7,12
ST   D13S317: 11,13
ST   D16S539: 11,15
ST   D21S11: 31
ST   D5S818: 8,11
ST   D7S820: 8
ST   TH01: 7
ST   TPOX: 8,9
ST   vWA: 17,18,21
DI   NCIt; C4910; Colon carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 21
//
RX   PubMed=7704014; DOI=10.1038/ng0195-10;
RA   da Costa L.T., Liu B., El-Deiry W.S., Hamilton S.R., Kinzler K.W.,
RA   Vogelstein B., Markowitz S.D., Willson J.K.V., de la Chapelle A.,
RA   Downey K.M., So A.G.;
RT   "Polymerase delta variants in RER colorectal tumours.";
RL   Nat. Genet. 9:10-11(1995).
//
RX   PubMed=7761852; DOI=10.1126/science.7761852;
RA   Markowitz S.D., Wang J., Myeroff L.L., Parsons R., Sun L.-Z.,
RA   Lutterbaugh J.D., Fan R.S., Zborowska E., Kinzler K.W., Vogelstein B.,
RA   Brattain M.G., Willson J.K.V.;
RT   "Inactivation of the type II TGF-beta receptor in colon cancer cells
RT   with microsatellite instability.";
RL   Science 268:1336-1338(1995).
//
RX   PubMed=8385345; DOI=10.1073/pnas.90.7.2846; PMCID=PMC46193;
RA   Smith K.J., Johnson K.A., Bryan T.M., Hill D.E., Markowitz S.D.,
RA   Willson J.K.V., Paraskeva C., Petersen G.M., Hamilton S.R.,
RA   Vogelstein B., Kinzler K.W.;
RT   "The APC gene product in normal and tumor cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:2846-2850(1993).
//
RX   PubMed=8755562; DOI=10.1073/pnas.93.15.7832; PMCID=PMC38834;
RA   Liu D.-C., Pearlman E., Diaconu E., Guo K., Mori H., Haqqi T.,
RA   Markowitz S.D., Willson J.K.V., Sy M.-S.;
RT   "Expression of hyaluronidase by tumor cells induces angiogenesis in
RT   vivo.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:7832-7837(1996).
//
RX   PubMed=9515795;
RA   Sparks A.B., Morin P.J., Vogelstein B., Kinzler K.W.;
RT   "Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal
RT   cancer.";
RL   Cancer Res. 58:1130-1134(1998).
//
RX   PubMed=9715273; DOI=10.1038/sj.onc.1201986;
RA   Eshleman J.R., Casey G., Kochera M.E., Sedwick W.D., Swinler S.E.,
RA   Veigl M.L., Willson J.K.V., Schwartz S., Markowitz S.D.;
RT   "Chromosome number and structure both are markedly stable in RER
RT   colorectal cancers and are not destabilized by mutation of p53.";
RL   Oncogene 17:719-725(1998).
//
RX   PubMed=11314036; DOI=10.1038/sj.onc.1204211;
RA   Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L.,
RA   Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R.,
RA   Minna J.D.;
RT   "Searching for microsatellite mutations in coding regions in lung,
RT   breast, ovarian and colorectal cancers.";
RL   Oncogene 20:1005-1009(2001).
//
RX   PubMed=12615714;
RA   Hempen P.M., Zhang L., Bansal R.K., Iacobuzio-Donahue C.A.,
RA   Murphy K.M., Maitra A., Vogelstein B., Whitehead R.H., Markowitz S.D.,
RA   Willson J.K.V., Yeo C.J., Hruban R.H., Kern S.E.;
RT   "Evidence of selection for clones having genetic inactivation of the
RT   activin A type II receptor (ACVR2) gene in gastrointestinal cancers.";
RL   Cancer Res. 63:994-999(2003).
//
RX   PubMed=17363507; DOI=10.1158/1535-7163.MCT-06-0555;
RA   Wang J., Kuropatwinski K.K., Hauser J., Rossi M.R., Zhou Y.-F., Conway A.,
RA   Kan J.L.C., Gibson N.W., Willson J.K.V., Cowell J.K., Brattain M.G.;
RT   "Colon carcinoma cells harboring PIK3CA mutations display resistance
RT   to growth factor deprivation induced apoptosis.";
RL   Mol. Cancer Ther. 6:1143-1150(2007).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//